Chugai's ALK Inhibitor "Alecensa®" Trial Stopped Early for Benefit

TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it received a recommendation by an independent data monitoring committee (IDMC) that the J-ALEX Study, a phase III study targeting ALK fusion gene positive non-small cell lung cancer (NSCLC) being conducted in Japan, should be stopped early as the study met its primary endpoint at a pre-planned interim analysis. The study showed that patients lived significantly longer without disease worsening (progression-fre
Source: BusinessWire-Primary

Chugai's ALK Inhibitor "Alecensa®" Trial Stopped Early for Benefit